Pyxis Oncology (PYXS) Return on Capital Employed (2021 - 2025)
Pyxis Oncology (PYXS) reported Return on Capital Employed of 109.03% for Q4 2025, down 5261.0% year-over-year from 2.11% in Q4 2024, and up 2.44% quarter-over-quarter from 111.75% in Q3 2025.
Pyxis Oncology (PYXS) Return on Capital Employed (2021 - 2025) Analysis & Trends
Pyxis Oncology (PYXS) has 5 years of Return on Capital Employed data on file, last reported at 109.03% in Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 109.03%, down 5261.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 109.03% (down 5261.0% YoY), and the FY2025 annual result was 81.79%, down 2125.0% from the prior year.
- Return on Capital Employed advanced to 109.03% in Q4 2025 per PYXS's latest filing, from 111.75% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 26.45% in Q1 2022 and troughed at 111.75% in Q3 2025.
- A 5-year average of 59.91% and a median of 56.42% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 3010 bps in 2024, then sank 7476 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 36.49% in 2021, then plunged by 82 bps to 66.39% in 2022, then climbed by 20 bps to 53.22% in 2023, then dropped by 6 bps to 56.42% in 2024, then sank by 93 bps to 109.03% in 2025.
- Business Quant data shows PYXS's Return on Capital Employed at 109.03% in Q4 2025, 111.75% in Q3 2025, and 95.19% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Pyxis Oncology | 125.84 Mn | 108.95 Mn | 8.65 Mn | -109.03% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -109.03% |
| Sep 30, 2025 | -111.75% |
| Jun 30, 2025 | -95.19% |
| Mar 31, 2025 | -80.83% |
| Dec 31, 2024 | -56.42% |
| Sep 30, 2024 | -37.00% |
| Jun 30, 2024 | -34.83% |
| Mar 31, 2024 | -36.56% |
| Dec 31, 2023 | -53.22% |
| Sep 30, 2023 | -67.09% |
| Jun 30, 2023 | -62.10% |
| Mar 31, 2023 | -60.94% |
| Dec 31, 2022 | -66.39% |
| Sep 30, 2022 | -47.60% |
| Jun 30, 2022 | -36.59% |
| Mar 31, 2022 | -26.45% |
| Dec 31, 2021 | -36.49% |